Journal of Affective Disorders
Volume 85, Issue 3 , Pages 275-282 , April 2005

Pretreatment pattern of symptom expression in premenstrual dysphoric disorder

  • Teri Pearlstein

      Affiliations

    • Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI, United States
    • Corresponding Author InformationCorresponding author. Women's Behavioral Health Program, Women and Infants Hospital, 101 Dudley St., Providence, RI 02905-2499, United States. Tel.: +1 401 453 7955; fax: +1 401 453 7720.
    • ,
  • Kimberly A. Yonkers

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States
    • ,
  • Rana Fayyad

      Affiliations

    • Pfizer Inc, New York, NY, United States
    • ,
  • John A. Gillespie

      Affiliations

    • Pfizer Inc, New York, NY, United States

Received 26 April 2004 ,Accepted 20 October 2004.

References 

  1. Angst J, Sellaro R, Stolar M, Merikangas KR, Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr. Scand. 2001;104:110–116
  2. Bloch M, Schmidt PJ, Rubinow DR. Premenstrual syndrome: evidence for symptom stability across cycles. Am. J. Psychiatry. 1997;154:1741–1746
  3. Chawla A, Swindle R, Long S, Kennedy S, Sternfeld B. Premenstrual dysphoric disorder: is there an economic burden of illness?. Med. Care. 2002;40:1101–1112
  4. Cohen LS, Miner C, Brown EW, Freeman E, Halbreich U, Sundell K, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet. Gynecol. 2002;100:435–444
  5. Dimmock PW, Wyatt KM, Jones PW, O'Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet. 2000;356:1131–1136
  6. Ekholm UB, Hammarbäck S, Bäckström T. Premenstrual syndrome: changes in symptom pattern between two menstrual cycles. J. Psychosom. Obstet. Gynaecol. 1992;13:107–119
  7. Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet. Gynecol. 2002;100:1219–1229
  8. Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder. Psychoneuroendocrinology. 2003;28(Suppl. 3):1–23
  9. Hsiao MC, Liu CY, Chen KC, Hsieh TT. Characteristics of women seeking treatment for premenstrual syndrome in Taiwan. Acta Psychiatr. Scand. 2002;106:150–155
  10. Hylan TR, Sundell K, Judge R. The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France. J. Women's Health Gend.-Based Med. 1999;8:1043–1052
  11. Menkes DB, Coates DC, Fawcett JP. Acute tryptophan depletion aggravates premenstrual syndrome. J. Affect. Disord. 1994;32:37–44
  12. Mira M, Abraham S, McNeil D, Vizzard J, Macaskill P, Fraser I, et al. The inter-relationship of premenstrual symptoms. Psychol. Med. 1995;25:947–955
  13. Robinson RL, Swindle RW. Premenstrual symptom severity: impact on social functioning and treatment-seeking behaviors. J. Women's Health Gend.-Based Med. 2000;9:757–768
  14. Roca CA, Schmidt PJ, Smith MJ, Danaceau MA, Murphy DL, Rubinow DR. Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. Am. J. Psychiatry. 2002;159:1876–1881
  15. Rubinow DR, Roy-Byrne P. Premenstrual syndromes: overview from a methodologic perspective. Am. J. Psychiatry. 1984;141:163–172
  16. Schnurr PP. Measuring amount of symptom change in the diagnosis of premenstrual syndrome. Psychol. Assess. 1989;1:277–283
  17. Shaver JF, Woods NF. Concordance of perimenstrual symptoms across two cycles. Res. Nurs. Health. 1985;8:313–319
  18. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, et al. Fluoxetine in the treatment of premenstrual dysphoric disorder. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N. Engl. J. Med. 1995;332:1529–1534
  19. Task Force on DSM-IV . Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. Washington, DC: American Psychiatric Press; 2000;
  20. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol. Med. 2002;32:119–132
  21. Yonkers KA, Halbriech U, Freeman E, Brown C, Endicott J, Frank E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. 1997;278:983–988
  22. Yonkers KA, Pearlstein T, Fayyad R, Gillespie JA. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. J. Affect. Disord. 2005;85:317–321

PII: S0165-0327(04)00367-2

doi: 10.1016/j.jad.2004.10.004

Journal of Affective Disorders
Volume 85, Issue 3 , Pages 275-282 , April 2005

Article Tools

* Image Usage & Resolution